Cargando…

Regulation of IFN-γ-mediated PD-L1 expression by MYC in colorectal cancer with wild-type KRAS and TP53 and its clinical implications

Introduction: In the tumor microenvironment, interferon gamma (IFN-γ) secreted by tumor infiltrating lymphocytes can upregulate programmed cell death 1 ligand 1 (PD-L1) expression in many cancers. The present study evaluated the expression of PD-L1 in selected colorectal cancer cell lines with IFN-γ...

Descripción completa

Detalles Bibliográficos
Autores principales:	Guo, Libin, Tang, Xiaoqiong, Wong, Sin Wa, Guo, Anyuan, Lin, Yao, Kwok, Hang Fai
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Pharmacology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9792609/ https://www.ncbi.nlm.nih.gov/pubmed/36582540 http://dx.doi.org/10.3389/fphar.2022.1022129

Ejemplares similares

The Roles of microRNAs in Regulating the Expression of PD-1/PD-L1 Immune Checkpoint
por: Wang, Qingshui, et al.
Publicado: (2017)

KRAS and TP53 Mutations in Colorectal Carcinoma
por: Al-Kuraya, Khawla S.
Publicado: (2009)

Induction of pancreatic neoplasia in the KRAS/TP53 Oncopig
por: Mondal, Pinaki, et al.
Publicado: (2023)

Clinical and Recent Patents Applications of PD-1/PD-L1 Targeting Immunotherapy in Cancer Treatment—Current Progress, Strategy, and Future Perspective
por: Guo, Libin, et al.
Publicado: (2020)

Unique volatolomic signatures of TP53 and KRAS in lung cells
por: Davies, M P A, et al.
Publicado: (2014)

TP53 /KRAS Co-Mutations Create Divergent Prognosis Signatures in Intrahepatic Cholangiocarcinoma
por: Guo, Chunguang, et al.
Publicado: (2022)

Simplified molecular classification of lung adenocarcinomas based on EGFR, KRAS, and TP53 mutations
por: Ruiz-Cordero, Roberto, et al.
Publicado: (2020)

hTERT, MYC and TP53 deregulation in gastric preneoplastic lesions
por: Silva, Tanielly Cristina Raiol, et al.
Publicado: (2012)

Expression of TP53 Isoforms p53β or p53γ Enhances Chemosensitivity in TP53(null) Cell Lines
por: Silden, Elisabeth, et al.
Publicado: (2013)

KRAS/LKB1 and KRAS/TP53 co-mutations create divergent immune signatures in lung adenocarcinomas
por: Gu, Meichen, et al.
Publicado: (2021)

KRAS, KIT and TP53 mutations in mother’s and daughter’s gastric cardia adenocarcinomas
por: Gluszek, Stanislaw, et al.
Publicado: (2018)

Genetic alterations of KRAS and TP53 in intrahepatic cholangiocarcinoma associated with poor prognosis
por: Peng, Jianbo, et al.
Publicado: (2023)

Expression signature based on TP53 target genes doesn't predict response to TP53-MDM2 inhibitor in wild type TP53 tumors
por: Sonkin, Dmitriy
Publicado: (2015)

MYC activation impairs cell-intrinsic IFNγ signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer
por: Alburquerque-Bejar, Juan J., et al.
Publicado: (2023)

“Double-Hit” Chronic Lymphocytic Leukemia, Involving the TP53 and MYC Genes
por: Nguyen-Khac, Florence
Publicado: (2022)

Efficient Correction of Oncogenic KRAS and TP53 Mutations through CRISPR Base Editing
por: Sayed, Shady, et al.
Publicado: (2022)

c-Myc plays a key role in IFN-γ-induced persistence of Chlamydia trachomatis
por: Vollmuth, Nadine, et al.
Publicado: (2022)

Distinct clinicopathological characteristics, genomic alteration and prognosis in breast cancer with concurrent TP53 mutation and MYC amplification
por: Lin, Xiaoyi, et al.
Publicado: (2022)

Recurrent, truncating SOX9 mutations are associated with SOX9 overexpression, KRAS mutation, and TP53 wild type status in colorectal carcinoma
por: Javier, Breanna M., et al.
Publicado: (2016)

Primary Resistance to Immune Checkpoint Blockade in an STK11/TP53/KRAS-Mutant Lung Adenocarcinoma with High PD-L1 Expression
por: Kwack, Won Gun, et al.
Publicado: (2020)

Expression of wild-type and mutated TP53 in breast carcinomas
por: Baumbusch, LO, et al.
Publicado: (2005)

CRISPR screens are feasible in TP53 wild‐type cells
por: Brown, Kevin R, et al.
Publicado: (2019)

Genomic Characterization of TP53–Wild-Type Esophageal Carcinoma()
por: Quaas, Alexander, et al.
Publicado: (2018)

MYC, FBXW7 and TP53 copy number variation and expression in Gastric Cancer
por: Calcagno, Danielle Queiroz, et al.
Publicado: (2013)

B‐prolymphocytic leukemia (B‐PLL) with genetic aberrations involving MYC and TP53
por: Tamber, Gurdip Singh, et al.
Publicado: (2021)

Mutational Analysis of KRAS, BRAF, and TP53 Genes of Ovarian Serous Carcinomas in Korean Women
por: Cho, Yun-Hyun, et al.
Publicado: (2009)

Reply to “CRISPR screens are feasible in TP53 wild‐type cells”
por: Haapaniemi, Emma, et al.
Publicado: (2019)

Myc-Induced Liver Tumors in Transgenic Zebrafish Can Regress in tp53 Null Mutation
por: Sun, Lili, et al.
Publicado: (2015)

ARF6 and AMAP1 are major targets of KRAS and TP53 mutations to promote invasion, PD-L1 dynamics, and immune evasion of pancreatic cancer
por: Hashimoto, Shigeru, et al.
Publicado: (2019)

Mitigating the Risk of t-MNs Development: TP53 or Not TP53?
por: Tesio, Melania
Publicado: (2023)

Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients
por: Fathi, Zahra, et al.
Publicado: (2018)

Prognostic value of KRAS/TP53/PIK3CA in non-small cell lung cancer
por: Zhao, Jiayi, et al.
Publicado: (2019)

KRAS and TP53 mutations in inflammatory bowel disease-associated colorectal cancer: a meta-analysis
por: Du, Lijun, et al.
Publicado: (2017)

The TP53 website: an integrative resource centre for the TP53 mutation database and TP53 mutant analysis
por: Leroy, Bernard, et al.
Publicado: (2013)

Nutlin-3a: A Potential Therapeutic Opportunity for TP53 Wild-Type Ovarian Carcinomas
por: Crane, Erin K., et al.
Publicado: (2015)

Maspin subcellular expression in wild-type and mutant TP53 gastric cancers
por: Gurzu, Simona, et al.
Publicado: (2020)

Wild-Type TP53 Predicts Poor Prognosis in Patients with Gastric Cancer
por: Deng, Wenhong, et al.
Publicado: (2021)

Wild-type p53 binds to MYC promoter G-quadruplex
por: Petr, Marek, et al.
Publicado: (2016)

MDM4 Overexpressed in Acute Myeloid Leukemia Patients with Complex Karyotype and Wild-Type TP53
por: Li, Li, et al.
Publicado: (2014)

TP53 and LRP1B Co-Wild Predicts Improved Survival for Patients with LUSC Receiving Anti-PD-L1 Immunotherapy
por: Yu, Jiangyong, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_glilao8eqdmo63d78k8gu36ir5